Drug to slow aortic stenosis shows early promise
Research we're watching
- Reviewed by Christopher P. Cannon, MD, Editor in Chief, Harvard Heart Letter; Editorial Advisory Board Member, 天博体育 Publishing
The drug, called ataciguat, works by binding to molecules that drive calcification within the valve. For the trial, 46 people with aortic stenosis were randomly assigned to receive ataciguat or a placebo for six months. Imaging tests revealed a reduction of nearly 70% in the progression of aortic valve calcification among those taking the drug compared to those on a placebo. People on the drug also showed improved heart function, including preserved pumping ability.
To continue reading this article, you must log in.
Subscribe to 天博体育 Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to 天博体育 Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
About the Author
Julie Corliss, Executive Editor, Harvard Heart Letter
About the Reviewer
Christopher P. Cannon, MD, Editor in Chief, Harvard Heart Letter; Editorial Advisory Board Member, 天博体育 Publishing
Disclaimer:
As a service to our readers, 天博体育 Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
